• Corpus ID: 57109696

Tratamiento anticoagulante oral. Estudio coste/beneficio*

@inproceedings{Navarroa2008TratamientoAO,
  title={Tratamiento anticoagulante oral. Estudio coste/beneficio*},
  author={Jos{\'e} L. Navarroa and Jes{\'u}s M. C{\'e}sara and {\'A}ngeles Fern{\'a}ndezb and Juan Carlos Reverter},
  year={2008}
}
Summary More than 1% of the population are on oral anticoagulant treatment (OAT), a figure which is growing by over 10% annually.The demand for the clinical and analytical services necessary for monitoring this treatment requires the assignment of significant economical and healthcare logistic resources. Comparative studies of the multiple control strategies (attending hospital, primary care or self-monitoring) should be set up, and should reflect not only the costs of their performance but… 

On the cost-effectiveness of dabigatran.

Cost of vitamin K antagonist anticoagulant treatment in patients with metallic prosthetic valve in mitral position

Most direct healthcare costs associated with the sampled patients arose from the specialist-care monitoring required for treatment, indicating that good monitoring is inversely related to direct Healthcare costs.

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Most direct health care costs associated with the sampled patients arise from the specialist-care monitoring required for the treatment, and good monitoring is inversely related to direct health Care costs.

Introducción del control terapéutico en el seguimiento de pacientes tratados con anticoagulantes orales Introduction of therapeutical control in follow-up of patients treated with oral anticoagulants

It was possible to demonstrate a good therapeutical control of anticoagulant treatment and also to improve services offered in the consultation specialized in control.

[Dabigatran versus acenocumarol for the prevention of stroke in atrial fibrillation: budget impact analysis in one health department in Spain].

The high budgetary impact of moving to a scenario of widespread substitution of warfarin for Dabigatran supports the restriction of this therapeutic strategy to subgroups of patients at high risk or difficult control.

s It Safe to Perform Joint Infiltrations or Aspirations in Patients nticoagulated With Acenocoumarol ?

The purpose of this study is to determine the rate of bleeding complications in patient’s anticoagulated with acenocoumarol according to the international normalized ratio (INR) coagulation index. A

Traumatismo cráneoencefálico (TCE) y anticoagulación. Aspectos esenciales Traumatic brain injury (TBI) and anticoagulation. Key points

An adequate initial assessment, a CT control only in case of neuro- logical damage and reversion of anticoagulation with prothrombin complex allow an effective management.

References

SHOWING 1-10 OF 65 REFERENCES

Optimal therapeutic anticoagulation.

Antiplatelet drugs given alone or in combination with anticoagulants have not been convincingly successful thus far in the prevention and treatment of thrombosis.

Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke.

For medical and economic reasons, anticoagulation treatment in the prevention of ischemic stroke is justified, and although older patients are more at risk of adverse events, antICOagulation is more cost-effective in this group.

Aging and oral anticoagulant therapy using acenocoumarol

We evaluated the influence of aging, gender and indications of anticoagulant therapy on acenocoumarol requirements in 1845 patients from 30 to 99 years old receiving acenocoumarol therapy who were

Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden

The objectives were to document the extent and timing of long-term complications and recurrent thromboembolism and to estimate the health care costs of treating these conditions.

Guidelines on oral anticoagulation: third edition

  • Medicine
    British journal of haematology
  • 1998
The revision of the 1990 oral anticoagulant guidelines by the British Committee for Standards in Haematology (BCSH) has been undertaken to reflect changes in the current medical literature and to incorporate the outcomes of medical audit.

Prevention of stroke in patients with nonvalvular atrial fibrillation

For AF patients considered to have a moderate risk of stroke, individual bleeding risk during anticoagulation and patient preference should particularly influence the choice of antithrombotic prophylaxis.

Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand?

More than half of the patients with atrial fibrillation admitted for acute stroke or TIA were not receiving any antithrombotic treatment beforehand, suggesting other reasons should be identified to improve stroke prevention in the community.

Non-rheumatic atrial fibrillation and stroke.

  • A. Tonkin
  • Medicine
    Australian and New Zealand journal of medicine
  • 1999
Embolic risk is greatest in those with increasing left atrial dilation, atrial dysfunction and LV dysfunction, and increasing age is associated with a greater incidence of structural heart disease and probably implies greater potential benefit with warfarin.

Epidemiology and Costs of Venous Diseases in Central Italy

Some 12% of the evaluated population sample (male population 46%) had or had been affected in the past by a venous problem and 50% of them had received some type of treatment.
...